

2nd European NTM & Bronchiectasis Workshop


Milan, Università Statale 01 - 03 July 2021

Powered by



Publi Créations

www.htmbronchiectasis.org



Dear colleagues and Partners,

In the last decade nontuberculous mycobacterial pulmonary disease and bronchiectasis have become hot topics.

The diagnosis of pulmonary nontuberculous mycobacterial disease and the decision to treat must incorporate several clinical, microbiological, and radiographic features. Although guidelines have been published to aid the clinician in making such decisions, the available evidence indicates that adherence to established guidelines is poor.

An increase in NTM pulmonary and extrapulmonary morbidity and mortality has been documented worldwide, especially among patients suffering from chronic respiratory diseases, including bronchiectasis, chronic obstructive pulmonary disease (COPD), or cystic fibrosis (CF), as well as among HIV-positive and other immunocompromised patients.

In the 10 years that have elapsed since the last multispecialty society guidelines were published, substantial work has been done by investigators worldwide in an attempt to answer key questions related to the epidemiology, prevention, diagnosis and treatment of NTM pulmonary disease. Despite the increased recognition of this group of microorganisms and the important role they play in chronic, pulmonary infectious disease, there are crucial unanswered questions that remain. A new set of European guidelines has been published and will be discussed at the meeting.

The prevalence of bronchiectasis in the UK rose by 40% between 2004 and 2014, with similar increases noted worldwide. Growing recognition of this disease is multifactorial, including through greater use of CT scanning, augmented awareness among clinicians, and the documented overlap between bronchiectasis, asthma, and chronic obstructive pulmonary disease (COPD). The increasing burden of bronchiectasis on health-care systems led to a surge in clinical research, new randomized trials, and global growth in specialist services.

In September 2017, the European Respiratory Society published guidelines for adult

bronchiectasis, which represent the first international standards of care for the disease following several national guidelines produced in the past decade. These guidelines show how far we still are from being able to deliver effective treatment in bronchiectasis.

Registries enrolling large numbers of patients are now reporting on patients from the United States and Europe and we have some insight into the disease in China as well. Our understanding of the microbiology of bronchiectasis is improving and important data have been published on the vicious cycle that relates inflammation and infection. New data on patients' quality of life and severity assessment will be discussed.

The role of macrolide and inhaled antibiotic therapies have been refined and the potential for new anti-inflammatory treatments are emerging.

Finally, collaborations between investigators in many parts of the world have yielded a better definition for a bronchiectasis exacerbation. The evolution of our understanding about this very heterogeneous disease is remarkable but we also await further translational studies and clinical trials to guide the care of individual patients.

There is a clear need for better education and improved knowledge of NTM pulmonary infection and bronchiectasis management.

The **2**nd **European NTM & Bronchiectasis Workshop** will give the opportunity to discuss and analyse the different diagnostic techniques, the role of new drugs and the optimal management of these two important diseases.

Yours sincerely,

Francesco BLASI



Professor of Respiratory Medicine & Head of the Department of Pathophysiology and Transplantation, University of Milan Head Internal Medicine Department, Respiratory Unit & Adult Cystic Fibrosis Center, Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico Milan Member of EMBARC (The European Bronchiectasis Network) Steering

Co-chair of IRIDE (Italian Registry of adult bronchiectasis) Co-chair of IRENE (Italian Observatory on NTM)

Powered by:





Stefano ALIBERTI (Italy) Francesco BLASI (Italy) James D. CHALMERS (UK)

SCIENTIFIC COMMITTEE Stuart ELBORN (UK)* Pieter C. GOEMINNE (Belgium) Antoni TORRES (Spain) Charles S. HAWORTH (UK)

Michael LOEBINGER (UK) **Tobias WELTE (Germany)**

VENUE

Università degli Studi di Milano Via Festa del Perdono 7 Tel. +39 02 503.12103

ORGANISING SECRETARIAT



PUBLI CREATIONS 74 Bd d'Italie, Monaco MC, 98000 (Monaco) Ph: +377 97 97 35 55 ntmbronchiectasis@publicreations.com



List of invited speakers will be published soon







TOPICS

Bronchiectasis

- **Cystic Fibrosis**
- Epidemiology
- Etiology
- Exacerbations
- **Imaging**
- **Immunology**

- **International Guidelines**
- Modifiable risk factors

NTM

- **Paediatrics**
- **Treatments**
- Surgery

SPECIALITIES

The congress programme has been designed to fulfill the educational and updating needs of professionals operating in the following specialities:

Respiratory Medicine
Infectious Diseases or
Virology
Internal Medicine
Radiology
Immunology

Transplant surgery
Physiotherapy or Respiratory
rehabilitation specialists
Biology or Microbiology
Specialized Nurses
Paediatricians

VENUE

The 2nd European NTM & Bronchiectasis Workshop will be held in the prestigious **University of Milan:**

Università degli Studi di Milano Via Festa del Perdono 7 Tel. +39 02 503.12103

For more information, please visit the website: www.unimi.it







July 1st, 2021

12.00 – 14.00	Registration
14.00 – 15.00	MEET THE PROFESSORS – ROUND 1 *
Room 1	Meet the Professors A NTM – PD: the challenging diagnostic path
Room 2	Meet the Professors B Physiotherapy: how to improve the management of bronchiectasis
Room 3	Meet the Professors C How to set up a PCD diagnostic service
Room 4	Meet the Professors D Immunodeficiency: from diagnosis to management
Room 5	Meet the Professors E How to use EMBARC data

^{*} The Meet the Professor Courses here reported are a proposal. Final titles will be communicated in January 2021.

15.00 – 16.00	MEET THE PROFESSORS – ROUND 2 Repetition of the "Meet the Professors" Courses of Round 1 in the same rooms.
16.00 – 16.30	WELCOME COFFEE

16.30 – 16.45 WELCOME ADDRESS
Chairs: A. Aliberti (Italy), F. Blasi (Italy), James D. Chalmers (UK)

RISING STAR SESSION

Chairs: A. Aliberti (Italy), F. Blasi (Italy), James D. Chalmers (UK)

Chairs. A. Anberti (Rary), 1. Diasi (Rary), sames D. Chairners (OK)	
16.45 – 17.00	Rising Star Oral presentation (Bronchiectasis)* The best abstract presented by a young clinician / researcher on Bronchiectasis Title to be announced
17.10 – 17.25	Rising Star Oral presentation (NTM-PD)* The best abstract presented by a young clinician / researcher on Bronchiectasis Title to be announced
17.35 – 17.45	Award Ceremony

^{*} Each lecture will be followed by 10-minute time for questions and comments as well as advices by the Chairmen.



July 1st, 2021

SESSION 1 – NTM GUIDELINES A STEP FORWARD?

Chairs: F. Blasi (Italy), TBD

17.45 – 18.00	Management of infections due to nontuberculous mycobacteria in solid organ transplant recipients - Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice .TBD
18.00 – 18.15	Nontuberculous mycobacterial pulmonary disease – The new ATS/ERS/ESCMID/IDSA Guidelines TBD
18.15 – 18.30	Discussion leaded by Stefano Aliberti (Italy)

KEYNOTE LECTURE 1

Chair: TBD

	NTM and Cystic Fibrosis: epidemiology and management of an old
18.30 – 19.10	enemy
10.30 13.10	TBD
	Discussion

19.10 – 20.00 STROLLING POSTER SESSION 1

20.00 – 21.00 **COCKTAIL**



July 2nd, 2021

KEYNOTE LECTURE 2

Chair: C.S. Haworth (UK)

09.00 – 09.40 Inhaled Amikacin: new data, new studies

SESSION 2 – HO Chairs: TBA	W TO PREVENT EXACERBATIONS OF BRONCHIECTASIS
09.40 – 10.00	Inhaled antibiotics: any good news? C. S. Haworth (UK)
10 .00 – 10.20	Macrolides: why, when, for how long P.C. Goeminne (Belgium)
10.20 - 10.40	Anti-inflammatory drugs: what's new? J.D. Chalmers (UK)
10.40 – 11.00	Discussion

11.00 – 11.30 **COFFEE**

KEYNOTE LECTURE 3

Chair: TBA

11.30 – 12.00 Bronchiectasis exacerbations management

KEYNOTE LECTURE 4

Chair: TBD

12.00 – 12.30	What's new from Willow Study J.D. Chalmers (UK)

12.30 – 13.30	SPONSORED SYMPOSIUM

13.30 – 14.30 **LUNCH**





July 2nd, 2021

	SESSION 3 – NTM TREATMENT Chairs: TBD		
	14.30 – 14.50	MAC-PD: Antibiotics treatment regimens TBD	
	14.50 – 15.10	NON MAC-PD: Antibiotic treatment regimens M. Loebinger (UK)	
	15.10 – 15.30	Discussion	
	15.30 – 16.30	SPONSORED SYMPOSIUM	
	16.30 – 17.00	COFFEE	
	SESSION 4 – RAI Panel: TBD	DIOLOGY MASTERCLASS	
	17.00 – 18.00	TBD	
	SESSION 5 – CYS Chairs: TBD	STIC FIBROSIS: A MODEL FOR AIRWAYS DISEASES?	
	18.00 – 18.20	Treatable and targetable traits TBD	
/	18.20 – 18.40	From genome to treatment TBD	
	18.40 – 19.00	Overview of therapeutics approaches TBA	
	19.00 – 19.20	Discussion	



July 3rd, 2021

SESSION 6 – LUNG TRANSPLANT

Chair: F. Blasi (Italy)

09.00 - 09.20	Lung transplantation in bronchiectasis and CF: indications and contraindications TBD
09.20 - 09.40	Impact of NTM-PD on lung transplantation TBD
09.40 - 10.00	Discussion

KEYNOTE LECTURE 5

Chair: TBD

	Lung Immunology: from bench to bedside
10.00 - 10.30	TBD
	Discussion

KEYNOTE LECTURE 6

Chair: TBD

10.30 – 11.00	TBD (On Alpha 1 ? or Bronchiectasis Studies)

11.00 – 11.30 **COFFEE**

	BEST ABSTRACTS ORAL PRESENTATIONS
11.30 – 12.30	Chairs: A. Torres (Spain), T. Welte (Germany)
	3-4 presentations

KEYNOTE LECTURE 7

Chair: C.S. Haworth (UK)

12.30 – 13.00	NTM-PD: Modificable risk factors TBD Discussion
13.00 – 13.20	AWARD AND CLOSING REMARKS All the chairs








N	O	T	E	S







2nd European NTM & Bronchiectasis Workshop

Milan, Università Statale 01 - 03 July 2021

Organised by



Publi Créations

74 Boulevard d'Italie, 98000 Monaco

Ph-: +377 97 97 35 55

ntmbronchiect as is @public reations.com

www.ntmbronchiectasis.org